Literature DB >> 33563899

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.

Valentín Garcia-Gutiérrez1, Alejandro Luna2, Juan M Alonso-Dominguez3, Natalia Estrada4, Concepcion Boque5, Blanca Xicoy4, Pilar Giraldo6, Anna Angona7, Alberto Alvarez-Larrán8, Fermin Sanchez-Guijo9, María José Ramírez10, Elvira Mora11, Patricia Vélez12, Ana Rosell13, Mercedes Colorado Araujo14, Beatriz Cuevas15, Miguel Sagüés4, Montserrat Cortes16, Manuel Perez Encinas17, Luis Felipe Casado Montero18, Melania Moreno Vega19, Luis Serrano20, Valle Gomez21, Carmen Garcia-Hernandez22, Sunil Lakhwani23, Antonio Paz Coll24, Raquel de Paz25, Sara Suarez-Varela26, Andrés Fernandez-Ruiz4, Raul Perez Lopez27, Almudena Ortiz-Fernández28, Antonio Jiménez-Velasco29, Juan Luis Steegmann-Olmedillas21, Juan Carlos Hernández-Boluda30.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33563899      PMCID: PMC7873237          DOI: 10.1038/s41408-021-00420-8

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN: 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  13 in total

1.  Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.

Authors:  Amr R Ibrahim; Christos Paliompeis; Marco Bua; Dragana Milojkovic; Richard Szydlo; Jamshid S Khorashad; Letizia Foroni; Alistair Reid; Hugues de Lavallade; Katayoun Rezvani; Francesco Dazzi; Jane F Apperley; John M Goldman; David Marin
Journal:  Blood       Date:  2010-09-10       Impact factor: 22.113

Review 2.  The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.

Authors:  Paul W Manley; Louise Barys; Sandra W Cowan-Jacob
Journal:  Leuk Res       Date:  2020-09-29       Impact factor: 3.156

Review 3.  Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.

Authors:  Massimo Breccia; Patrizia Pregno; Paolo Spallarossa; Eleonora Arboscello; Fabio Ciceri; Mauro Giorgi; Alberto Grossi; Mario Mallardo; Savina Nodari; Stefano Ottolini; Carla Sala; Giovanni Tortorella; Gianantonio Rosti; Fabrizio Pane; Giorgio Minotti; Michele Baccarani
Journal:  Ann Hematol       Date:  2016-09-30       Impact factor: 3.673

4.  The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.

Authors:  Andrew A Wylie; Joseph Schoepfer; Wolfgang Jahnke; Sandra W Cowan-Jacob; Alice Loo; Pascal Furet; Andreas L Marzinzik; Xavier Pelle; Jerry Donovan; Wenjing Zhu; Silvia Buonamici; A Quamrul Hassan; Franco Lombardo; Varsha Iyer; Michael Palmer; Giuliano Berellini; Stephanie Dodd; Sanjeev Thohan; Hans Bitter; Susan Branford; David M Ross; Timothy P Hughes; Lilli Petruzzelli; K Gary Vanasse; Markus Warmuth; Francesco Hofmann; Nicholas J Keen; William R Sellers
Journal:  Nature       Date:  2017-03-22       Impact factor: 49.962

5.  The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.

Authors:  Laura N Eadie; Verity A Saunders; Susan Branford; Deborah L White; Timothy P Hughes
Journal:  Oncotarget       Date:  2018-02-03

6.  Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.

Authors:  Andreas Hochhaus; Carlo Gambacorti-Passerini; Camille Abboud; Bjørn Tore Gjertsen; Tim H Brümmendorf; B Douglas Smith; Thomas Ernst; Pilar Giraldo-Castellano; Ulla Olsson-Strömberg; Susanne Saussele; Nathalie Bardy-Bouxin; Andrea Viqueira; Eric Leip; T Alexander Russell-Smith; Jocelyn Leone; Gianantonio Rosti; Justin Watts; Francis J Giles
Journal:  Leukemia       Date:  2020-06-22       Impact factor: 11.528

Review 7.  Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.

Authors:  Andreas Hochhaus; Massimo Breccia; Giuseppe Saglio; Valentín García-Gutiérrez; Delphine Réa; Jeroen Janssen; Jane Apperley
Journal:  Leukemia       Date:  2020-05-04       Impact factor: 11.528

Review 8.  Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety.

Authors:  Valentín García-Gutiérrez; Juan Carlos Hernández-Boluda
Journal:  Front Oncol       Date:  2019-07-03       Impact factor: 6.244

Review 9.  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Authors:  A Hochhaus; M Baccarani; R T Silver; C Schiffer; J F Apperley; F Cervantes; R E Clark; J E Cortes; M W Deininger; F Guilhot; H Hjorth-Hansen; T P Hughes; J J W M Janssen; H M Kantarjian; D W Kim; R A Larson; J H Lipton; F X Mahon; J Mayer; F Nicolini; D Niederwieser; F Pane; J P Radich; D Rea; J Richter; G Rosti; P Rousselot; G Saglio; S Saußele; S Soverini; J L Steegmann; A Turkina; A Zaritskey; R Hehlmann
Journal:  Leukemia       Date:  2020-03-03       Impact factor: 11.528

View more
  5 in total

1.  Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.

Authors:  Huan-Chau Lin; Ferry Saputra; Gilbert Audira; Yu-Heng Lai; Marri Jmelou M Roldan; Honeymae C Alos; Charlaine A Aventurado; Ross D Vasquez; Guan-Jhe Tsai; Ken-Hong Lim; Chung-Der Hsiao
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

2.  Asciminib in chronic myeloid leukemia: many questions still remain to be answered.

Authors:  Ahmet Emre Eşkazan
Journal:  Blood Cancer J       Date:  2021-04-29       Impact factor: 11.037

3.  New Imidazole-Based N-Phenylbenzamide Derivatives as Potential Anticancer Agents: Key Computational Insights.

Authors:  M Shaheer Malik; Reem I Alsantali; Qazi Mohammad Sajid Jamal; Zaki S Seddigi; Moataz Morad; Meshari A Alsharif; Essam M Hussein; Rabab S Jassas; Munirah M Al-Rooqi; Zainularifeen Abduljaleel; Ahmed O Babalgith; Hatem M Altass; Ziad Moussa; Saleh A Ahmed
Journal:  Front Chem       Date:  2022-01-19       Impact factor: 5.221

Review 4.  Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia.

Authors:  Adelina Fernandes; Naranie Shanmuganathan; Susan Branford
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

Review 5.  Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia.

Authors:  Govinda Poudel; Molly G Tolland; Timothy P Hughes; Ilaria S Pagani
Journal:  Cancers (Basel)       Date:  2022-07-06       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.